Literature DB >> 17696806

Alterations in drug disposition during pregnancy: implications for drug therapy.

Lucy S Hodge1, Timothy S Tracy.   

Abstract

The disposition of many medications is altered during pregnancy. Due to changes in many physiological parameters as well as variability in the activity of maternal drug-metabolizing enzymes, the efficacy and toxicity of drugs used by pregnant women can be difficult to predict. Enzymatic activity exhibited by the placenta and fetus may affect maternal drug distribution and clearance also. In addition, efflux transporters have been detected in high amounts within placental tissue, potentially limiting fetal exposure to xenobiotics. Dosage adjustments of antiepileptic drugs, antidepressants and anti-infectives administered during pregnancy have been required due to these changes in drug metabolism and disposition. As such, pregnant women may require different dosing regimens than both men and non-pregnant women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696806     DOI: 10.1517/17425225.3.4.557

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  39 in total

1.  Altered cytochrome P450 expression in mice during pregnancy.

Authors:  Kwi Hye Koh; Hui Xie; Ai-Ming Yu; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2010-10-22       Impact factor: 3.922

2.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

3.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

4.  Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Jashvant D Unadkat
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

5.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

Review 6.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 7.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

8.  Alteration of the expression of pesticide-metabolizing enzymes in pregnant mice: potential role in the increased vulnerability of the developing brain.

Authors:  Marie C Fortin; Lauren M Aleksunes; Jason R Richardson
Journal:  Drug Metab Dispos       Date:  2012-12-04       Impact factor: 3.922

9.  Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.